Vertex Extends Portfolio Pricing and Reimbursement Approach To Denmark

Vertex has succeeded in bringing its portfolio-based approach to the pricing and reimbursement of its cystic fibrosis treatments to another market, Denmark. This follows similar deals in Ireland and Sweden.

Denmark
Vertex Strikes Cystic Fibrosis Treatment Deal In Denmark

Vertex has expanded the pool of countries where it has negotiated a “portfolio-based” pricing and reimbursement deal for its products. The company has reached an agreement in Denmark, where the public procurement body, Amgros, is keen to explore new ways of tackling high drug prices.

The deal will give access to all Vertex’ current CFTR modulator medicines, including Orkambi (lumacaftor/ivacaftor) and Kalydeco (ivacaftor) as well...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography